Notification

Error

Estradiol patches rival standard ADT in locally advanced prostate cancer

User
Posted 17 Nov 2026 at 08:59

"Transdermal estradiol patches may offer men with locally advanced prostate cancer an effective alternative to standard androgen deprivation therapy (ADT), with patients experiencing similar cancer outcomes but fewer hot flushes, according to results from a large phase 3 trial. Researchers found that the patches were non-inferior to luteinising hormone-releasing hormone (LHRH) agonists for preventing metastasis or death over three years, while substantially reducing one of ADT’s most troublesome side effects. The trial enrolled 1360 UK men with histologically confirmed locally advanced, non-metastatic prostate cancer who were commencing long-term ADT between 2007 and 2022. They were randomised to receive estradiol patches (n=721) or standard LHRH agonists (n=639). The median participant age was 72 years, with 85% having T3 disease and 65% having node-negative disease at enrolment. Most participants (60%) had Gleason scores of 8 to 10, reflecting a predominantly high-risk population. Participants continued to receive evolving standard-of-care treatment throughout the study, including prostate radiotherapy and, later, concomitant docetaxel for selected patients. Three-year metastasis-free survival was 87.1% among patients treated with patches, compared with 85.9% in the LHRH agonist group. The hazard ratio for confirmed metastasis or death was 0.96, meeting the study’s predefined criteria for non-inferiority. Overall survival was also comparable; at five years, 81.1% of patch patients were alive compared with 79.2% of those receiving LHRH agonists, with no statistically significant difference between groups (HR 0.90; 95% CI 0.75-1.07). The investigators also found that both approaches were equally effective at suppressing testosterone. Among patients who remained on their allocated treatment, 85% in each group maintained castrate testosterone levels throughout the first year. LHRH agonists have long been the cornerstone of ADT but suppress both testosterone and estradiol, contributing to hot flushes, bone loss, metabolic changes, and other adverse effects. Transdermal estradiol suppresses testosterone while maintaining circulating estrogen levels, potentially avoiding some complications of estrogen depletion. Unlike oral estrogen, transdermal delivery bypasses first-pass liver metabolism and is associated with a lower thromboembolic risk. The side-effect profile differed substantially between treatments. Hot flushes occurred in 44% of men using estradiol patches compared with 89% of those receiving LHRH agonists. Moderate-to-severe hot flushes (grade 2 or higher) were reported by just 8% of patients treated with estradiol, compared with 37% of those receiving standard therapy. Related However, estradiol treatment was associated with considerably higher rates of gynecomastia. Breast enlargement occurred in 85% of patients receiving patches compared with 42% of those treated with LHRH agonists, while moderate-to-severe cases occurred in 37% and 9%, respectively. Rates of erectile dysfunction and reduced libido were similar between treatment groups, affecting approximately two-thirds of patients regardless of treatment. Serious adverse events were uncommon and comparable between the groups. Grade 3 or higher adverse events occurred in 16% of patients receiving estradiol and 19% receiving LHRH agonists. “The patches appear to be as effective as standard LHRH agonists against prostate cancer and are associated with a lower incidence of the short-term and long-term deleterious adverse events related to estrogen depletion during treatment with LHRH agonists,” authors concluded. “Given these findings, tE2 patches can be considered an alternative choice for testosterone suppression in men with metastasis stage M0 and nodal stage N0 or N+ prostate cancer.” Although gynecomastia remains an important limitation of estradiol therapy, the researchers said the reduction in hot flushes and other estrogen-depletion effects may make transdermal estradiol an attractive option for some men. They added that the differing side-effect profiles and routes of administration should form part of shared decision-making when selecting androgen deprivation therapy."

Synopsis of NEJM article published in March 2026.

This is my intended path when my PSA progresses and mets unable to be dealt with by radiation. 

Is anyone else also considering and or partaking in this approach?

Edited by moderator 17 Nov 2026 at 09:55  | Reason: Shortened link and added speech marks to show quoted text.

User
Posted 17 Nov 2026 at 15:02

Interesting stuff. Thanks for sharing. I guess it might take a while for NHS guidance to reflect the results of this trial. I wonder if it will be made available for those who have metastatic PC or just those at earlier stages who were included in this trial.

User
Posted 17 Nov 2026 at 22:43
Interesting especially that guys still got hot flushes, my missus has them and they stopped hers!
User
Posted 18 Nov 2026 at 03:24

Originally Posted by: Online Community Member

Interesting stuff. Thanks for sharing. I guess it might take a while for NHS guidance to reflect the results of this trial. I wonder if it will be made available for those who have metastatic PC or just those at earlier stages who were included in this trial.

Estradiol patches in my view does provide a viable option for men with Stage 4 mets, with an efficacy consistent with LHRH agonists, but mitigating several side effects, especially hot flushes both in ocurence and severity. Antidotal evidence from patients so treated, is of a lessened libido response as compared to LHRH agonists as well. Whilst now authorised in the US, Prescribing guidelines require ratification in numerous countries including my own, Australia. 

Whilst not earth shattering, Estradiol is a welcome addition to the PCa treatment arsenal.  

 
Forum Jump  
©2026 Prostate Cancer UK